Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rucaparib in Metastatic Breast Cancer with BRCAness
NCT02505048Phase 2Completed
- Sponsor
- Unicancer
- Start
- Mar 2016
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rucaparib in breast cancer, sponsored by Unicancer. Primary endpoint: Clinical Benefit Rate at 3 years. Started Mar 2016; status: completed.
02
Drugs
rucaparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02505048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02505048.